


Axinn Obtains Stipulated Summary Judgment of Non-Infringement for Zydus

NEWS | LESS THAN 1 MIN READ

January 20, 2016

Axinn successfully obtained a stipulated order of non-infringement regarding a patent asserted against its client, Zydus, in ongoing patent litigation concerning generic versions of Abilify® (aripiprazole). Otsuka markets Abilify® and had filed an amended complaint adding infringement allegations related to U.S. Patent No. 8,759,350, which the Court dismissed without prejudice. Otsuka then filed a second amended complaint against Zydus adding the '350 patent. Before Zydus answered the second amended complaint, the Court construed the claims of the '350 patent favorably for Zydus. In light of this favorable claim construction, Axinn succeeded in negotiating a stipulated summary judgment of non-infringement concerning the '350 patent.

Related People



Jason Murata

Related Services

Intellectual Property

To subscribe to our publications, [click here](#).

Featured Insights

- GCR Live: Law Leaders Europe 2025
SPEAKING ENGAGEMENT ANTITRUST
- AHLA Annual Meeting 2025
SPEAKING ENGAGEMENT ANTITRUST
- SABA North America Annual Conference 2025
SPEAKING ENGAGEMENT ANTITRUST
- Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses
WEBINAR ANTITRUST
- Volunteer Lawyers for the Arts – Champions of the Arts Awards and Gala 2025
SPONSORSHIP ANTITRUST
- NJSBA Annual Meeting and Convention 2025
SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY
- Cost-Effective and Efficient IP Litigation Strategies – Making Paragraph IV Litigation Work for You
WEBINAR INTELLECTUAL PROPERTY
- Hartford HealthCare Black and Red Gala 2025
SPONSORSHIP ANTITRUST
- Informa CompLaw Antitrust West Coast Conference 2025
SPEAKING ENGAGEMENT ANTITRUST

- Recent Decision Shows the Heavy Burden of Actual Malice in Defamation Suits
- AXINN VIEWPOINTS LITIGATION & TRIALS**

© 2025 Axinn, Veltrop & Harkrider LLP. All Rights Reserved